WuXi Biologics (Cayman) Inc. (WXIBF)
OTCMKTS
· Delayed Price · Currency is USD
2.960
-0.420 (-12.43%)
At close: Jun 10, 2025
WuXi Biologics Employees
WuXi Biologics had 12,575 employees as of December 31, 2024. The number of employees decreased by 165 or -1.30% compared to the previous year.
Employees
12,575
Change (1Y)
-165
Growth (1Y)
-1.30%
Revenue / Employee
$203,466
Profits / Employee
$36,564
Market Cap
14.38B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Elite Pharmaceuticals | 64 |
Tian'an Technology Group | 8 |
CytoDyn | 9 |
Glass House Brands | 374 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
WuXi Biologics News
- 3 days ago - WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu - PRNewsWire
- 15 days ago - Hong Kong stocks jump as US blocks Trump’s tariffs in win for global trade - South China Morning Post
- 25 days ago - WuXi Biologics: Eyes On Long-Term Risks And Near-Term Outlook (Rating Downgrade) - Seeking Alpha
- 27 days ago - WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA - PRNewsWire
- 6 weeks ago - Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report - PRNewsWire
- 7 weeks ago - WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year - PRNewsWire
- 7 weeks ago - WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou ... - GuruFocus
- 7 weeks ago - WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site - PRNewsWire